Faecal calprotectin in colonic diverticular disease: a case–control study
Authors:
- 22 October 2008
- journal article
- research article
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 24 (1) , 49-55
Abstract
Information about faecal calprotectin (FC) in colonic diverticular disease (DD) are lacking. We assessed FC in colonic DD, comparing it with irritable bowel syndrome (IBS) patients and healthy controls. Moreover, we compared FC levels in different degrees of DD and assessed FC in symptomatic DD before and after treatment.Keywords
This publication has 26 references indexed in Scilit:
- Assessment and Grading of Mucosal Inflammation in Colonic Diverticular DiseaseJournal of Clinical Gastroenterology, 2008
- Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical IndicesAmerican Journal of Gastroenterology, 2008
- New physiopathological and therapeutic approaches to diverticular disease of the colonExpert Opinion on Pharmacotherapy, 2007
- Review article: biological activity markers in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2007
- Mesalazine and/or Lactobacillus casei in Preventing Recurrence of Symptomatic Uncomplicated Diverticular Disease of the ColonJournal of Clinical Gastroenterology, 2006
- Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular DiseaseDigestive Diseases and Sciences, 2005
- The Natural History of DiverticulitisJournal of Clinical Gastroenterology, 2004
- Acute diverticulitis of the colon – current medical therapeutic managementExpert Opinion on Pharmacotherapy, 2004
- Diagnosis and treatment of diverticular diseaseSurgical Endoscopy, 1999
- Assessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic StudyScandinavian Journal of Gastroenterology, 1992